4//SEC Filing
Revance Therapeutics, Inc. 4
Accession 0001209191-17-032203
CIK 0001479290operating
Filed
May 11, 8:00 PM ET
Accepted
May 12, 7:46 PM ET
Size
8.1 KB
Accession
0001209191-17-032203
Insider Transaction Report
Form 4
BYRNES ROBERT F
Director
Transactions
- Award
Stock Option (Right to Buy)
2017-05-11+6,000→ 6,000 totalExercise: $20.90Exp: 2027-05-10→ Common Stock (6,000 underlying) - Award
Common Stock
2017-05-11+3,000→ 3,000 total
Holdings
- 13,665(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 11, 2018, subject to Mr. Byrnes' Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date.
- [F2]The shares subject to the stock option shall vest on the one year anniversary, May 11, 2018, subject to Mr. Byrnes' Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual option grant pursuant to the Compensation Policy.
Documents
Issuer
Revance Therapeutics, Inc.
CIK 0001479290
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001479290
Filing Metadata
- Form type
- 4
- Filed
- May 11, 8:00 PM ET
- Accepted
- May 12, 7:46 PM ET
- Size
- 8.1 KB